Clinical Trial Detail

NCT ID NCT03331562
Title A SU2C Catalyst Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Translational Genomics Research Institute
Indications

pancreatic adenocarcinoma

Therapies

Pembrolizumab

Paricalcitol + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.